Collaboration has been and will continue to be an important strategy and priority for BioArctic, as exemplified by our successful existing partnerships with Eisai and lecandemab, which is the first approved disease-modifying drug in the largest global markets. Additionally, the recent deal with Bristol Myers Squibb, which includes BioArctic’s BrainTransporter technology that enables active transport of biological drugs into the brain.
BioArctic is an attractive partner and with our broad project portfolio and promising results from the BrainTransporter technology, we are actively working to establish new partnerships in various forms.
BioArctic develops antibodies against misfolded proteins in the central nervous system
BioArctic is a world leader in the development of innovative antibodies against aggregated and misfolded proteins that cause disorders of the central nervous system. After having developed lecanemab, which is the world’s first diseasemodifying drug against Alzheimer’s disease, the goal is now to continue driving development forward in both Alzheimer’s disease and other neurodegenerative diseases.
The BrainTransporter technology enables a new generation of treatments for brain diseases
BioArctic’s BrainTransporter technology facilitates active transport of biological drugs into the brain, which has the potential to both drastically improve their effect and reduce the risk of side effects. In 2024, BioArctic was able to present validating preclinical results for its BrainTransporter technology, which shows that the company is on the way to solving one of the greatest challenges in the development of new drugs against diseases of the central nervous system.
